[Adjuvant chemotherapy in XXXX of the gastrointestinal tract (GIT)].

@entity1 @entity788 @entity5 @entity957 @entity189 @entity1820 @entity418 @entity694 @entity356 @entity1487
A critical review of adjuvant therapies of @entity1820 shows that this is a field of active clinical investigation. Unfortunately the results that have been achieved until now have not fulfilled the expectations. Neoadjuvant therapies of @entity957 of the esophagus and the anus in many cases lead to pathologically documented complete remissions. After a 10 years follow-up, it is evident that for @entity189 such pathological complete remissions translate into longterm remissions and eventually cures. The same conclusion, however, can not yet be drawn for @entity418 . The role of adjuvant chemotherapy in @entity356 remains unclear. The results of the current FAM-studies are eagerly awaited. In @entity788 the combination of radiotherapy and @entity1487 may probably prolong disease-free survival and survival for a limited time period. Many adjuvant studies have been done in @entity694 , without any conclusive data regarding the role of chemotherapy. Some indications point to biological response modifiers, immuno- and regional therapies to be effective in the adjuvant situation. The results of adjuvant chemotherapy in @entity5 after radiotherapy or radiochemotherapy are easier to judge. They show that some @entity1 profit from adjuvant therapy. But the most efficient combinations and the role of newer modalities remain to be elucidated (Fig. 8 a-8c).
